Vitamin D and Dementia: High Daily Doses Linked to Better Cognitive Test Scores in Seniors

<>

Older adults with mild cognitive impairment and sleep disturbances who take a daily vitamin D dose of at least 5,000 International Units score significantly higher on cognitive tests, according to a study published in the journal Sleep Medicine. Researchers found an average 13 percent increase in test scores among high-dose participants.

The investigation, published in the peer-reviewed journal Sleep Medicine, tracked 54 older adults with a clinical diagnosis or suspected presentation of mild cognitive impairment (MCI). Participants had a mean age of 67.2 years, with men comprising 46 percent of the cohort. A defining characteristic of the study group was the presence of co-occurring sleep disturbances—a clinical overlap that researchers note frequently compounds the trajectory of cognitive deterioration.

To quantify cognitive performance, the investigative team utilized the Montreal Cognitive Assessment (MoCA), a validated screening instrument designed to detect deficits in memory, visuospatial processing, executive function, and language. Statistical modeling revealed that participants consuming a daily vitamin D intake of at least 5,000 International Units (IU)—equivalent to 125 micrograms—scored an average of 3.78 points higher on the MoCA than the comparison group. These calculations controlled for potential confounding variables, including participant age, sex, educational attainment, body mass index (BMI), and the specific chemical form of vitamin D utilized.

In Plain English: The Clinical Takeaway

• The Dosage Threshold: Statistically significant improvements in cognitive scores appeared exclusively among participants taking 5,000 IU or more daily; lower doses showed no measurable correlation.
• Observational Nature: Because participants reported their own supplement intake rather than receiving controlled dosages, researchers emphasize that a direct cause-and-effect relationship cannot be definitively established.
• Target Population: The findings apply specifically to older adults experiencing both mild cognitive impairment and sleep disturbances, rather than the general healthy population.

Study Parameter	Clinical Detail
Sample Size (N)	54 older adults
Mean Age	67.2 years
Primary Assessment Tool	Montreal Cognitive Assessment (MoCA)
Identified Dose Threshold	≥ 5,000 International Units (IU) daily
Observed Test Score Variance	+3.78 points (~13% increase)

References

Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider regarding any questions about a medical condition or nutritional supplement regimen.